MX2023013148A - Iptacopan para el tratamiento del sindrome uremico hemolitico atipico. - Google Patents
Iptacopan para el tratamiento del sindrome uremico hemolitico atipico.Info
- Publication number
- MX2023013148A MX2023013148A MX2023013148A MX2023013148A MX2023013148A MX 2023013148 A MX2023013148 A MX 2023013148A MX 2023013148 A MX2023013148 A MX 2023013148A MX 2023013148 A MX2023013148 A MX 2023013148A MX 2023013148 A MX2023013148 A MX 2023013148A
- Authority
- MX
- Mexico
- Prior art keywords
- iptacopan
- uremic syndrome
- treatment
- hemolytic uremic
- atypical hemolytic
- Prior art date
Links
- 208000035913 Atypical hemolytic uremic syndrome Diseases 0.000 title abstract 3
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 title abstract 3
- 229940071142 iptacopan Drugs 0.000 title abstract 2
- JUWBBUFSAGEROP-VVJLZRNGSA-N 4-[(2S,4S)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-2-yl]benzoic acid hydrate hydrochloride Chemical compound CCO[C@@H]1C[C@@H](C(C=C2)=CC=C2C(O)=O)N(CC(C2=C(C(C)=C3)NC=C2)=C3OC)CC1.O.Cl JUWBBUFSAGEROP-VVJLZRNGSA-N 0.000 abstract 1
- 229940125397 factor b inhibitor Drugs 0.000 abstract 1
- 229940007667 lnp023 Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- External Artificial Organs (AREA)
Abstract
En el presente documento se describen métodos para tratar el síndrome urémico hemolítico atípico (aHUS) con el inhibidor del factor B LNP023 (iptacopan) o una sal farmacéuticamente aceptable del mismo, p. ej., clorhidrato de iptacopan.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163185742P | 2021-05-07 | 2021-05-07 | |
| PCT/IB2022/054237 WO2022234541A1 (en) | 2021-05-07 | 2022-05-06 | Iptacopan for the treatment of atypical hemolytic uremic syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023013148A true MX2023013148A (es) | 2023-11-28 |
Family
ID=81750354
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013148A MX2023013148A (es) | 2021-05-07 | 2022-05-06 | Iptacopan para el tratamiento del sindrome uremico hemolitico atipico. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240238266A1 (es) |
| EP (1) | EP4333845A1 (es) |
| JP (1) | JP2024517234A (es) |
| KR (1) | KR20240004947A (es) |
| CN (1) | CN117479937A (es) |
| AU (1) | AU2022269405A1 (es) |
| CA (1) | CA3218914A1 (es) |
| IL (1) | IL308166A (es) |
| MX (1) | MX2023013148A (es) |
| WO (1) | WO2022234541A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11951101B2 (en) | 2020-07-16 | 2024-04-09 | Novartis Ag | Methods of using factor B inhibitors |
| TW202523695A (zh) | 2023-11-22 | 2025-06-16 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於治療非酒精性脂肪性肝病之方法及組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3425B1 (ar) | 2013-07-15 | 2019-10-20 | Novartis Ag | مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b |
| AU2018326768B2 (en) * | 2017-08-31 | 2021-07-29 | Novartis Ag | Novel uses of piperidinyl-indole derivatives |
| TWI858258B (zh) * | 2020-05-18 | 2024-10-11 | 瑞士商諾華公司 | Ｌｎｐ０２３之結晶形式 |
-
2022
- 2022-05-06 KR KR1020237041804A patent/KR20240004947A/ko active Pending
- 2022-05-06 WO PCT/IB2022/054237 patent/WO2022234541A1/en not_active Ceased
- 2022-05-06 EP EP22724907.5A patent/EP4333845A1/en active Pending
- 2022-05-06 US US18/558,766 patent/US20240238266A1/en active Pending
- 2022-05-06 JP JP2023567878A patent/JP2024517234A/ja active Pending
- 2022-05-06 AU AU2022269405A patent/AU2022269405A1/en active Pending
- 2022-05-06 CA CA3218914A patent/CA3218914A1/en active Pending
- 2022-05-06 MX MX2023013148A patent/MX2023013148A/es unknown
- 2022-05-06 CN CN202280042482.XA patent/CN117479937A/zh active Pending
- 2022-05-06 IL IL308166A patent/IL308166A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4333845A1 (en) | 2024-03-13 |
| CA3218914A1 (en) | 2022-11-10 |
| AU2022269405A1 (en) | 2023-11-16 |
| IL308166A (en) | 2024-01-01 |
| WO2022234541A1 (en) | 2022-11-10 |
| JP2024517234A (ja) | 2024-04-19 |
| KR20240004947A (ko) | 2024-01-11 |
| CN117479937A (zh) | 2024-01-30 |
| US20240238266A1 (en) | 2024-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021006011A (es) | Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma. | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2020010697A (es) | Kit, composicion y terapia de combinacion para el sindrome del cromosoma x fragil. | |
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| MX2023001071A (es) | Tratamiento de la migraña. | |
| PH12021551317A1 (en) | Modulators of trex1 | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| MX2020013352A (es) | Tratamiento para migrañas. | |
| PH12022550130A1 (en) | Enzyme inhibitors | |
| MX2023013148A (es) | Iptacopan para el tratamiento del sindrome uremico hemolitico atipico. | |
| WO2020051532A3 (en) | Macrocyclic compounds for the treatment of medical disorders | |
| MX2022007626A (es) | Combinaciones. | |
| PH12021550883A1 (en) | Crystalline salts of a plasma kallikrein inhibitor | |
| WO2023122260A3 (en) | Inhibitors of sars-cov-2 | |
| ZA202307855B (en) | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome | |
| MX2024010644A (es) | Uso de iptacopan para el tratamiento de la nefritis lupica. | |
| MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
| PH12019550154B1 (en) | Azetidine derivative | |
| CR20240023A (es) | Compuestos de sulfonimidamida y usos de los mismos | |
| MX2025006240A (es) | Composicion farmaceutica para la prevencion o tratamiento contra ulcera peptica relacionada a farmacos, que comprende zastaprazan o una sal farmaceuticamente aceptable del mismo | |
| EP4234022A3 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject | |
| ZA202004849B (en) | Therapeutic agents for treating restless legs syndrome | |
| WO2021102359A3 (en) | Taspase1 inhibitors and uses thereof | |
| ZA202407245B (en) | Novel use of pitolisant for treating severe fatigue | |
| ZA201908087B (en) | Treatment for migraine |